A5012663149- Immune cells in cancer
- Cancer Immunotherapy and Biomarkers
- Cytokine Signaling Pathways and Interactions
- Cancer Research and Treatments
- Inflammatory Biomarkers in Disease Prognosis
- Immunotherapy and Immune Responses
Novartis (United States)
2023
Abstract High levels of IL1β can result in chronic inflammation, which turn promote tumor growth and metastasis. Inhibition could therefore be a promising therapeutic option the treatment cancer. Here, effects blockade induced by mAbs canakinumab gevokizumab were evaluated alone or combination with docetaxel, anti–programmed cell death protein 1 (anti–PD-1), anti-VEGFα, anti-TGFβ syngeneic humanized mouse models cancers different origin. Canakinumab did not show notable efficacy as...
<div>Abstract<p>High levels of IL-1β can result in chronic inflammation, which turn promote tumor growth and metastasis. Inhibition could therefore be a promising therapeutic option the treatment cancer. Here, effects blockade induced by monoclonal antibodies canakinumab gevokizumab were evaluated alone or combination with docetaxel, anti-PD-1, anti-VEGFα anti-TGFβ syngeneic humanized mouse models cancers different origin. Canakinumab did not show notable efficacy as single-agent...
<div>Abstract<p>High levels of IL-1β can result in chronic inflammation, which turn promote tumor growth and metastasis. Inhibition could therefore be a promising therapeutic option the treatment cancer. Here, effects blockade induced by monoclonal antibodies canakinumab gevokizumab were evaluated alone or combination with docetaxel, anti-PD-1, anti-VEGFα anti-TGFβ syngeneic humanized mouse models cancers different origin. Canakinumab did not show notable efficacy as single-agent...
<div>Abstract<p>High levels of IL1β can result in chronic inflammation, which turn promote tumor growth and metastasis. Inhibition could therefore be a promising therapeutic option the treatment cancer. Here, effects blockade induced by mAbs canakinumab gevokizumab were evaluated alone or combination with docetaxel, anti–programmed cell death protein 1 (anti–PD-1), anti-VEGFα, anti-TGFβ syngeneic humanized mouse models cancers different origin. Canakinumab did not show notable...
<div>Abstract<p>High levels of IL1β can result in chronic inflammation, which turn promote tumor growth and metastasis. Inhibition could therefore be a promising therapeutic option the treatment cancer. Here, effects blockade induced by mAbs canakinumab gevokizumab were evaluated alone or combination with docetaxel, anti–programmed cell death protein 1 (anti–PD-1), anti-VEGFα, anti-TGFβ syngeneic humanized mouse models cancers different origin. Canakinumab did not show notable...